Purpose of Review: This review discusses the current understanding of cardiotoxicities and prevention strategies for several agents including anthracyclines, HER2 monoclonal antibodies, tyrosine kinase inhibitors, and fluoropyrimidines. Recent Findings: Heart disease and cancer are by far the most common causes of death in the USA and may coincide in a given individual. Life-prolonging therapies for heart disease and cancer continue to evolve, with a particular proliferation of new agents to treat cancer. These advances in the treatment of cancer have led to an expanding population of cancer survivors. Due to the natural coincidence of heart disease and cancer and due to the cardiotoxicities of certain chemotherapies, it is increasingly important for cardiologists and oncologists to understand and anticipate cardiovascular events in the setting of cancer treatment. Summary: A growing body of literature on the incidence of, prediction of, and prevention of cardiotoxicity in the cancer patient is now available.
- Cardiotoxicity and cancer patients
- Left ventricular ejection fraction (LVEF)